Author: Ojosnegros, Samuel; Beerenwinkel, Niko
Title: Models of RNA virus evolution and their roles in vaccine design Document date: 2010_11_3
ID: 0q928h3b_33
Snippet: The STEP vaccine trials were designed to test the efficiency of a T cell vaccine in reducing viremia and enhancing the cellular immune response [96] . This vaccine candidate is a therapeutic vaccine (see below), because it was intended to enhance the immune response against HIV even if sterilizing immunity would not be achieved. The STEP vaccine formulation was based in an adenovirus serotype 5 vector (Ad5). The vaccine included three independent.....
Document: The STEP vaccine trials were designed to test the efficiency of a T cell vaccine in reducing viremia and enhancing the cellular immune response [96] . This vaccine candidate is a therapeutic vaccine (see below), because it was intended to enhance the immune response against HIV even if sterilizing immunity would not be achieved. The STEP vaccine formulation was based in an adenovirus serotype 5 vector (Ad5). The vaccine included three independent Ad5 vectors, each one carrying one of the three HIV proteins Gag, Pol, and Nef. Although in early phases of the clinical trials, the vaccine was proven to elicit specific anti-HIV T cell responses, no significant protection was conferred to people receiving the vaccine in phase IIb trials. Indeed, individuals having immune memory against the Ad5 vector were more susceptible to infection by HIV [97] . This unexpected result was probably due to an adding-fuel-to-the-fire effect, in which the Ad5 vector activated T cells creating a suitable environment for HIV replication [98] .
Search related documents:
Co phrase search for related documents- adenovirus serotype and cell response: 1, 2, 3, 4
- adenovirus serotype and cell vaccine: 1, 2, 3, 4, 5, 6
- adenovirus serotype and early phase: 1
- adenovirus serotype and immune response: 1, 2, 3, 4, 5
- adenovirus serotype and significant protection: 1
- cell response and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- cell response and early phase: 1, 2, 3, 4, 5, 6, 7, 8, 9
- cell response and HIV immune response: 1, 2, 3, 4, 5, 6
- cell response and HIV protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- cell response and HIV replication: 1, 2, 3, 4, 5, 6
- cell response and immune memory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- cell response and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- cell response and significant protection: 1, 2, 3
- cell vaccine and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- cell vaccine and early phase: 1, 2, 3, 4
- cell vaccine and HIV immune response: 1
- cell vaccine and HIV protein: 1, 2, 3, 4, 5, 6, 7
- cell vaccine and HIV replication: 1
- cell vaccine and iib trial: 1
Co phrase search for related documents, hyperlinks ordered by date